Atezolizumab for Recurrent Glioblastoma (MOAB Trial)
This study, called the MOAB Trial, is looking at whether a drug called atezolizumab can help people with recurrent glioblastoma (a type of brain cancer that has come back). Researchers want to see if giving atezolizumab before surgery is beneficial, especially for patients who have a low tumor mutational burden (TMB), which is a measure of changes in the cancer's DNA. You might be able to join if you are at least 18 years old and have recurrent glioblastoma that has been confirmed by a doctor. The main goal is to see if atezolizumab can help people live longer. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 80 participants. It is designed to compare survival in groups with low and high TMB.
- What's involved
- One dose of atezolizumab will be given before surgery. A diagnostic biopsy may be required if there is uncertainty about MRI findings.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the start of atezolizumab treatment until death or leaving the study, for up to 24 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
At a glance
Conditions
Where it's being run
4 sites across 4 statesStudy leadership
- Mustafa Khasraw, MD · PRINCIPAL_INVESTIGATOR · Duke University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Median survival within the low and high TMB groupsDay 1 of atezolizumab treatment until death or off study due to any other reason whichever comes first, assessed for up to 24 months. If the patient is alive at the time of analysis, survival will be censored at the time of last follow-up.
Survival of the prospectively treated patient is defined as the time between initiation of atezolizumab and death. If the patient is alive at the time of analysis, survival will be censored at the time of last follow-up.
- Median survival within the low and high TMB groups and their respective matched historical control groupDay 1 of atezolizumab treatment until death or off study due to any other reason whichever comes first, assessed for up to 24 months. If the patient is alive at the time of analysis, survival will be censored at the time of last follow-up.
For comparisons between prospectively treated patients and their matched historical control groups, OS for prospectively treated patients will be measured from the date of atezolizumab until death or last contact. Survival for the matched group is defined as the time between the date of 1st recurrence and death or last contact.